Physiotherapy Review

Pełna treść

4/2024 vol. 28
Artykuł przeglądowy

Medical cannabis in the management of musculoskeletal pain: a systematic review of clinical trials

Przemysław Płatek 1
,
Laura Jadwiga Piejko 2, 3
  1. Physiotherapy Faculty, The Jerzy Kukuczka Academy of Physical Education, Katowice, Poland
  2. Department of Clinical Physiotherapy, Clinical Unit of Physiotherapy in Psychiatry, The Jerzy Kukuczka Academy of Physical Education, Katowice, Poland
  3. Clinical Unit of Physiotherapy, Clinical Mental Health Hospital SPZOZ in Rybnik, Rybnik, Poland
Physiotherapy Review, 2024, 28(4), 5-16
DOI: https://doi.org/10.5114/phr.2024.145972
Data publikacji online: 2024/12/20
Plik artykułu
art1_4_2024.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Ritchie CS, Patel K, Boscardin J, Miaskowski C, Vranceanu AM, Whitlock E, Smith A. Impact of persistent pain on function, cognition, and well-being of older adults. J Am Geriatr Soc. 2023; 71 (1): 26–35.
  2. Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. Br J Anaesth. 2019; 123 (2): e273–e283.
  3. de Barros GAM, Pos AM, Sousa ÂM, Pereira CL, Nobre CDA, Palmeira CCA, et al. Cannabinoid products for pain management: recommendations from the São Paulo State Society of Anesthesiology. Braz J Anesthesiol. 2024; 74 (4): 844513.
  4. Boehnke KF, Häuser W, Fitzcharles MA. Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain). Curr Rheumatol Rep. 2022; 24 (7): 238–246.
  5. Stella B, Baratta F, Della Pepa C, Arpicco S, Gastaldi D, Dosio F. Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain. Drugs. 2021; 81 (13): 1513–1557.
  6. Matarazzo AP, Elisei LMS, Carvalho FC, Bonfilio R, Ruela ALM, Galdino G, et al. Mucoadhesive nanostructured lipid carriers as a cannabidiol nasal delivery system for the treatment of neuropathic pain. Eur J Pharm Sci. 2021; 159: 105698.
  7. Ang SP, Sidharthan S, Lai W, Hussain N, Patel KV, Gulati A, et al. Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks. Pain Ther. 2023; 12 (2): 355–375.
  8. Stefano GB, Quinn E, Kream RM. Endocannabinoid Stimulated Release of Nitric Oxide and its Mito- chondrial Influence Triggering Vascular Pathology. Pharm Anal Acta. 2015; 6 (6): 378.
  9. Maida V, Shi RB, Fazzari FGT, Zomparelli L. Topical cannabis-based medicines - A novel paradigm and treatment for non-uremic calciphylaxis leg ulcers: An open label trial. Int Wound J. 2020; 17 (5): 1508–1516.
  10. Mallick-Searle T, St Marie B. Cannabinoids in Pain Treatment: An Overview. Pain Manag Nurs. 2019; 20 (2): 107–112.
  11. Bell AD, MacCallum C, Margolese S, Walsh Z, Wright P, Daeninck PJ, et al. Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. Cannabis Cannabinoid Res. 2024; 9 (2): 669–687.
  12. Maayah ZH, Takahara S, Ferdaoussi M, Dyck JRB. The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation. Biochim Biophys Acta Mol Basis Dis. 2020; 1866 (7): 165771.
  13. Rodriguez CEB, Ouyang L, Kandasamy R. Antinociceptive effects of minor cannabinoids, terpenes and flavonoids in Cannabis. Behav Pharmacol. 2022; 33 (2&3): 130–157.
  14. Safi K, Sobieraj J, Błaszkiewicz M, Żyła J, Salata B, Dzierżanowski T. Tetrahydrocannabinol and Cannabidiol for Pain Treatment-An Update on the Evidence. Biomedicines. 2024; 29; 12 (2): 307.
  15. Burdinski DCL, Kodibagkar A, Potter K, Schuster RM, Evins AE, Ghosh SS, et al. Year-Long Cannabis Use for Medical Symptoms and Brain Activation During Cognitive Processes. JAMA Netw Open. 2024; 7 (9): e2434354.
  16. Boehnke KF, Yakas L, Scott JR, DeJonckheere M, Litinas E, Sisley S, et al. A mixed methods analysis of cannabis use routines for chronic pain management. J Cannabis Res. 2022; 4 (1): 7.
  17. Francis A, Erridge S, Holvey C, Coomber R, Holden W, Rucker J, et al. Assessment of Clinical Outcomes in Patients With Osteoarthritis: Analysis From the UK Medical Cannabis Registry. J Pain Palliat Care Pharmacother. 2024; 38 (2): 103–116.
  18. USA Arthritis Foundation – blog.arthritis.org. Patients Tell Us About CBD Use. [updated 8th August 2019]. Available from: https://www.arthritis.org/news/patients-tell-us-cbd-use. Accessed 02/07/2024.
  19. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag. 2009; 5 (5): 257–286.
  20. Harris D, Jones RT, Shank R, Nath R, Fernandez E, Goldstein K, Mendelson J. Self-reported marijuana effects and characteristics of 100 San Francisco medical marijuana club members. J Addict Dis. 2000; 19 (3): 89–103.
  21. Furrer D, Kröger E, Marcotte M, Jauvin N, Bélanger R, Ware M, et al. Cannabis against chronic musculoskeletal pain: a scoping review on users and their perceptions. J Cannabis Res. 2021; 3 (1): 41.
  22. Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J. 2005; 4; 2: 18.
  23. Narayanan V, Gandhi R, Suryavanshi A, Nadkarni B, Rungta V. Topical cannabinoids for the management of musculoskeletal pain: Understanding and review. Int J Ortop Res. 2022; 83–88.
  24. Polish Drug base: https://www.mp.pl/pacjent/ leki/lek/88409,Sativex-aerozol-do-stosowania-w-jamie-ustnej. Accessed 02/08/2024.
  25. Potts AJ, Cano C, Thomas SHL, Hill SL. Synthetic cannabinoid receptor agonists: classification and nomenclature. Clin Toxicol (Phila). 2020; 58 (2): 82–98.
  26. Poisblaud L, Kröger E, Jauvin N, Pelletier-Jacob J, Bélanger RE, et al. Perceptions and Preoccupations of Patients and Physicians Regarding Use of Medical Cannabis as an Intervention Against Chronic Musculoskeletal Pain: Results from a Qualitative Study. J Pain Res. 2023; 16: 3463–3475.
  27. Matos AP, Pegorari MS. How to Classify Clinical Trials Using the PEDro Scale? J Lasers Med Sci. 2020; 11 (1): 1–2.
  28. Heineman JT, Forster GL, Stephens KL, Cottler PS, Timko MP, DeGeorge BR Jr. A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. J H Hand Surg Am. 2022; 47 (7): 611–620.
  29. Nitecka-Buchta A, Nowak-Wachol A, Wachol K, Walczyńska-Dragon K, Olczyk P, Batoryna O, Kempa W, Baron S. Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial. J Clin Med. 2019; 8 (11): 1886.
  30. Hunter D, Oldfield G, Tich N, Messenheimer J, Sebree T. Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis. Osteoarthr Cartil. 2018; 26 (1): S26.
  31. Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020; 132 (1): 56–61.
  32. Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PLoS One. 2017: 16; 12 (11): e0187795.
  33. Bawa Z, Lewis D, Gavin PD, Libinaki R, Joubran L, El-Tamimy M, Taylor G, Meltzer R, Bedoya-Pérez M, Kevin RC, McGregor IS. An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Sci Rep. 2024: 23; 14 (1): 11792.
  34. Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E. The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain. 2016; 32 (12): 1036–1043.
  35. O’Brien K, Beilby J, Frans M, et al. Medicinal cannabis for pain: Real-world data on three-month changes in symptoms and quality of life. Drug Science, Policy and Law 2023; (9): 1–12.
  36. Mangual-Pérez D, Tresgallo-Parés R, RamírezGonzález M, Torres-Lugo NJ, Rivera-Dones A, Rivera-Rodríguez G, Claudio-Marcano A, Lojo-Sojo L. Patient Experience and Perspective on Medical Cannabis as an Alternative for Musculoskeletal Pain Management. J Am Acad Orthop Surg Glob Res Rev. 2022; 6 (7): e22.00055.
  37. Holt A, Nouhravesh N, Strange JE, Kinnberg Nielsen S, Schjerning AM, et al. Cannabis for chronic pain: cardiovascular safety in a nationwide Danish study. Eur Heart J. 2024; 45 (6): 475–484.
  38. Safakish R, Ko G, Salimpour V, Hendin B, Sohanpal I, Loheswaran G, Yoon SYR. Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study. Pain Med. 2020; 21 (11): 3073–3086.
  39. Bellnier T, Brown GW, Ortega TR. Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis. Ment Health Clin. 2018; 8 (3): 110–115.
  40. Klimkiewicz A. (ed.). Konopie i medyczne zastosowanie kannabinoidów – praktyczne rekomendacje [Cannabis and the medical use of cannabinoids - practical recommendations]. Ewdomed 2022.
  41. Johal H, Vannabouathong C, Chang Y, Zhu M, Bhandari M. Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use? Ther Adv Musculoskelet Dis. 2020; 12: 1759720X20937968.
  42. O'Connor CM, Anoushiravani AA, Adams C, Young JR, Richardson K, Rosenbaum AJ. Cannabinoid Use in Musculoskeletal Illness: A Review of the Current Evidence. Curr Rev Musculoskelet Med. 2020; 13 (4): 379–384.
  43. Food Public Warning by National Sanitary Inspectorate about hemp olis: https://www.gov.pl/web/gis/ ostrzezenie-publiczne-dotyczace-zywnosci-stwierdzenie-niedozwolonego-ekstraktu-z-konopi-wloknistych-oraz-zawartosc-9-tetrahydrokannabinol-9-thc-na-poziomie-09-gkg-12-gkg-15-gkgw-produktach-pn-premium-quality-hemp-oil-olejek-konopny-10-5-ml-i-10-ml-oraz-premium-quality-hemp-oil-dietary-supplement-olejek-konopny5cbd-5-ml-i-10-ml. Accessed 02/09/2024.
  44. Ochmańska K.Pietrosiuk A. The importance of cannabinoids in modern medicine. Lek Pol. 2022: 12; 33–38. [Article in Polish].
  45. Frane N, Stapleton E, Iturriaga C, Ganz M, Rasquinha V, Duarte R. Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study. J Cannabis Res. 2022; 4 (1): 47.
  46. Senderovich H, Wagman H, Zhang D, Vinoraj D, Waicus S. The Effectiveness of Cannabis and Cannabis Derivatives in Treating Lower Back Pain in the Aged Population: A Systematic Review. Gerontology. 2022; 68 (6): 612–624.
  47. Madden K, van der Hoek N, Chona S, George A, Dalchand T, Baldawi H, et al. Cannabinoids in the Management of Musculoskeletal Pain: A Critical Review of the Evidence. JBJS Rev. 2018; 6 (5): e7.
  48. Fitzcharles MA, Ste-Marie PA, Häuser W, Clauw DJ, Jamal S, Karsh J, et al. Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2016; 68 (5): 681–6818.
PUBLISHER
Udostępnij
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications